The Senate Judiciary Committee will hold a hearing Nov. 30 to examine Mylan's agreement to pay the federal government $465 million to settle potential claims that the big drug company shortchanged Medicaid over rebates for sales of the anti-allergy EpiPen devices.

The less Mylan and the Justice Department say about their big settlement over EpiPen, the more Congress wants to hear about it.

The hearing was called by committee chairman Sen. Chuck Grassley, R-Iowa. He is just one of several senators who has expressed frustration over the deal, with some calling for more disclosure about yet-to-be-signed agreement or for it to be scrapped altogether.

The quickly arranged settlement announced by Mylan on Oct. 7 allows the company to escape potential criminal prosecution over the matter, avoid having to admit any wrongdoing, and to not pay a higher rebate rate for EpiPen until next spring.

"Mylan's management of the EpiPen has not only led to higher costs for patients and their families, but also for taxpayers in Iowa and across the nation by misclassifying its product to dodge higher Medicaid rebate requirements," Grassley said.

"Americans deserve to know what the government is doing to hold Mylan accountable, recoup lost tax dollars and prevent similar behavior in the future," Grassley said.

A press release from Grassley's office noted that key details of the agreement and the background for it have yet to be revealed.

They include the question of where Mylan's payment is "proportional to what Mylan overcharged taxypayers," as well as "how much of the settlement would be returned to the states," who with the federal government jointly run Medicaid, which covers primarily poor people.

Another question is how much, if any, penalties under the federal False Claims Act would apply to the deal.

Mylan and the Justice Department also have refused to reveal what rebate rate the company will pay for EpiPen starting in April.

A list of witnesses for the Senate committee hearing has yet to be announced.

In addition to looking at the Mylan deal, Grassley said the hearing will look at whether the federal government is doing enough with its current authority to prevent drug companies from misrepresenting their products to government programs, and what officials are doing to hold companies accountable for that.

A spokeswoman for Mylan declined to comment on the hearing. In the past, the company has declined to reveal additional details about the agreement, as has the Justice Department.